Brainstorm Cell Therapeutics Inc Cash Flow Reinvestment Rate

Latest as of June 2018: 236.96x

Brainstorm Cell Therapeutics Inc cash flow reinvestment rate. Brainstorm Cell Therapeutics Inc (BCLI) has a Cash Flow Reinvestment Rate of 236.96x as of June 2018, reinvesting $13.03 Million (capex $215.00K plus investments $-12.82 Million) from operating cash flow of $55.00K. See BCLI financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Reinvestment Rate

236.96x

(Capex + Investments) / Operating CF

Total Reinvested

$13.03 Million

Capex + Investments

Operating Cash Flow

$55.00K

USD

Capital Expenditures

$215.00K

USD

Brainstorm Cell Therapeutics Inc Cash Flow Reinvestment Rate by Year (None–None)

Brainstorm Cell Therapeutics Inc cash flow reinvestment rate by year from None to None. Year-by-year capital reinvestment analysis for Brainstorm Cell Therapeutics Inc. For the full cash flow conversion analysis, see Brainstorm Cell Therapeutics Inc (BCLI) cash conversion ratio.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow